Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib plus abiraterone acetate and prednisone versus placebo plus abiraterone acetate and prednisone in HRR-mutated metastatic castration-sensitive prostate cancer
CTR20210814Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of niraparib, abiraterone, prednisone in prostate cancer (PCa), sponsored by Janssen Pharmaceutical. Started Aug 2021; status: active.
02
Drugs
niraparibabirateroneprednisone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20210814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210814.